Skip to content

Masked Comparison of a New PEG Based Artificial Tear and Optive for Comfort, Vision & Wear Time in Patients Wearing Contact Lenses

Phase 4 Masked Comparison of a New PEG Based Artificial Tear and Optive for Comfort, Vision & Wear Time in Patients Wearing Contact Lenses

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00570843
Enrollment
50
Registered
2007-12-11
Start date
2008-03-31
Completion date
2010-02-28
Last updated
2010-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comfort, Vision and Wear Time

Brief summary

The objective of this study is to evaluate the effect of a new PEG based artificial tear as compared to Optive on comfort, wear time, and vision in patients wearing contact lenses.

Interventions

DRUGNew PEG based artificial tear

1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)

DRUGOptive

1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)

Sponsors

Bp Consulting, Inc
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Use of soft contact lenses (e.g. silicone hydrogel lenses, daily disposables etc.) and multipurpose solution for cleaning, including enzyme-based cleaners (ClearCare etc.) * Able to wear contact lenses for approximately 10-12 hours/day * Willingness to complete entire length of trial and comply with subjective questionnaire.

Exclusion criteria

* Patients taking topical cyclosporine (Restasis) * Patients currently using Optive for dryness relief. * Patients wearing hard or rigid gas permeable lenses * Patients with uncontrolled systemic disease which may confound the results of the trial.

Design outcomes

Primary

MeasureTime frame
Comfort1 month

Secondary

MeasureTime frame
vision and wear time1 month

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026